David Lebwohl

CIK: 0001810882

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (40.0%)

Position reduction

Option Exercises (M)1 (20.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NTLA

Intellia Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

NTLA
Intellia Therapeutics, Inc.
Mar 1, 2026
Award(A)
Direct
9.9K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
11.9K shares at avg. $9.21$110K
NTLA
Intellia Therapeutics, Inc.
Mar 1, 2025
Award(A)
Direct
43.2K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 3, 2025
Sale(S)
Direct
9.6K shares at avg. $12.18$116K
NTLA
Intellia Therapeutics, Inc.
Jan 1, 2025
Exercise(M)
Direct
3.2K shares-

		Type	Shares	Price		Ownership
Mar 1, 2026	NTLA Intellia Therapeutics, Inc.	Award(A)	9,943	-	$0	Direct
Jan 5, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	11,903	$9.21	$109,627	Direct
Mar 1, 2025	NTLA Intellia Therapeutics, Inc.	Award(A)	43,200	-	-	Direct
Jan 3, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	9,557	$12.18	$116,404	Direct
Jan 1, 2025	NTLA Intellia Therapeutics, Inc.	Exercise(M)	3,189	-	$0	Direct

1-5 of 5 transactions

About Lebwohl David

Lebwohl David (SEC CIK 0001810882) files insider reports with the SEC as EVP, Chief Medical Officer of Intellia Therapeutics, Inc. (NTLA).

Signal8 holds 5 ownership filings by Lebwohl David, all Form 4s, filed between Jan 3, 2025 and Mar 3, 2026. Those filings report 5 transactions, from Jan 1, 2025 to Mar 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lebwohl David's filings is in CAMBRIDGE, MA.

Recent filings by Lebwohl David

Mar 1, 2026: Grant or award of NTLA shares (Form 4, code A).
Jan 5, 2026: Open-market sale of NTLA shares (Form 4, code S).
Mar 1, 2025: Grant or award of NTLA shares (Form 4, code A).
Jan 3, 2025: Open-market sale of NTLA shares (Form 4, code S).
Jan 1, 2025: Option exercise of NTLA shares (Form 4, code M).

Other insiders filing for Intellia Therapeutics, Inc. (NTLA)

Marantz Jing L., EVP, Chief Medical Officer
Dube Michael P, VP, Chief Accounting Officer
LEONARD JOHN M, President and CEO
Dulac Edward J III, EVP, Chief Financial Officer
Verwiel Frank, Director
Keresty Georgia, Director

How to read Form 4 transaction codes